跳到正文
原文
Bayer AG· @Bayer · X·· 22 天前精选AI 评分78
AI 导读

拜耳宣布,中国CDE已批准其新药asundexian用于降低卒中风险,该药此前获得优先审评。据拜耳官网信息,asundexian是首个获批的因子XIa抑制剂。

推荐理由

拜耳披露其因子XIa抑制剂经优先审评在中国获批用于降低卒中风险,读者可据此了解该机制药物在国内的准入进展。

正文

#NEWS: China’s Center of Drug Evaluation (CDE) has granted approval for our new drug for stroke risk reduction, following Priority Review. https://www.bayer.com/media/en-us/asundexian-first-factor-xia-inhibitor-approved-in-china-for-stroke-risk-reduction-after-priority-review/

来源:Bayer AG · x.com